| | Reference | Published | View |
|---|
| Yurista 2020 Cardiovasc Diabetol | Yurista SR, Silljé HHW, Rienstra M, de Boer RA, Westenbrink BD (2020) Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes? Cardiovasc Diabetol 19:5. | 2020 | PMID: 31910841 Open Access |
| Shao 2019 Cardiovasc Diabetol | Shao Q, Meng L, Lee S, Tse G, Gong M, Zhang Z, Zhao J, Zhao Y, Li G, Liu T (2019) Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induce diabetic rats. Cardiovasc Diabetol 18:165. | 2019 | PMID: 31779619 Open Access |
| Zhang 2018 Cardiovasc Diabetol | Zhang X, Zhang Z, Yang Y, Suo Y, Liu R, Qiu J, Zhao Y, Jiang N, Liu C, Tse G, Li G, Liu T (2018) Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits. Cardiovasc Diabetol 17:160. | 2018 | PMID: 30591063 Open Access |
| Hughey 2013 Cardiovasc Diabetol | Hughey CC, Ma L, James FD, Bracy DP, Wang Z, Wasserman DH, Rottman JN, Hittel DS, Shearer J (2013) Mesenchymal stem cell transplantation for the infarcted heart: therapeutic potential for insulin resistance beyond the heart. Cardiovasc Diabetol 12:128. | 2013 | PMID: 24007410 Open Access |
